Search This Blog

Friday, August 22, 2014

FDA approves Jardiance® (empagliflozin) tablets for adults with type 2 diabetes (NYSE:LLY)

RIDGEFIELD, Conn., and INDIANAPOLISAug. 1, 2014 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) and Eli Lilly and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) approved Jardiance® (empagliflozin) tablets as an adjunct to diet and exercise to improve glycemic control, or blood glucose levels, in adults with type 2 diabetes (T2D). JARDIANCE is not for people with type 1 diabetes or for people with diabetic ketoacidosis (increased ketones in the blood or urine).



FDA approves Jardiance® (empagliflozin) tablets for adults with type 2 diabetes (NYSE:LLY)

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.